研究者
J-GLOBAL ID:202301007937616581   更新日: 2023年07月31日

今吉 菜月

イマヨシ ナツキ | Imayoshi Natsuki
所属機関・部署:
職名: 助教
競争的資金等の研究課題 (1件):
  • 2020 - 2023 BRD4及びCBP/p300を標的とした小児MLL白血病に対する新規治療法の開発
論文 (3件):
  • Natsuki Imayoshi, Makoto Yoshioka, Kuniaki Tanaka, Shyh-Ming Yang, Koshi Akahane, Yuki Toda, Shigekuni Hosogi, Takeshi Inukai, Seiji Okada, David J Maloney, et al. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochemical and biophysical research communications. 2022. 590. 49-54
  • Keigo Amari, Satoru Sasagawa, Natsuki Imayoshi, Yuki Toda, Shigekuni Hosogi, Toshihiko Imamura, Eishi Ashihara. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Biochemical and biophysical research communications. 2022. 588. 147-153
  • Natsuki Imayoshi, Makoto Yoshioka, Jay Chauhan, Susumu Nakata, Yuki Toda, Steven Fletcher, Jeffrey W Strovel, Kazuyuki Takata, Eishi Ashihara. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Biochemical and biophysical research communications. 2017. 484. 2. 262-268
MISC (3件):
  • 芦原 英司, 今吉 菜月, Yoshioka Makoto, 中田 晋, Chauhan Jay, 戸田 侑紀, Fletcher Steven, Strovel Jeffrey, 高田 和幸. 新規治療薬 基礎 新規ブロモドメイン阻害剤CG13250の多発性骨髄腫に対する抗腫瘍効果. International Journal of Myeloma. 2017. 7. 1. 41-41
  • Natsuki Imayoshi, Makoto Yoshioka, Susumu Nakata, Jay Chauhan, Yoko Kado, Yuki Toda, Steven Fletcher, Jeffrey Strovel, Kazuyuki Takata, Eishi Ashihara. A Novel BRD4 Inhibitor CA2 Suppresses MM Cell Proliferation in an Orthotopic Myeloma Mouse Model. BLOOD. 2016. 128. 22
  • Eishi Ashihara, Ryoko Oki, Natsuki Imayoshi, Makoto Yoshioka, Jeffrey Strovel, Ayako Honjo, Yumi Sakai, Tetsuya Takada, Jay Chauhan, Mithun Raje, et al. Novel Bromodomain Inhibitors Suppress Proliferation of Multiple Myeloma Cells. BLOOD. 2015. 126. 23
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る